Abstract
Tumor-targeted therapies such as trastuzumab have led to significant improvements in survival of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, these therapies have also been associated with significant left ventricular dysfunction. The incidence of trastuzumab-induced heart failure has decreased significantly since the initial reports, in large part due to improved screening, closer monitoring for early changes in left ventricular function, and a significant decrease in the concurrent administration of anthracyclines. The mechanism of trastuzumab cardiotoxicity is still not well understood, but current knowledge suggests that ErbB2 inhibition in cardiac myocytes plays a key role. In addition to trastuzumab and other HER2-targeted agents, vascular endothelial growth factor inhibitors, proteasome inhibitors, and immune checkpoint inhibitors are all additional classes of drugs used with great success in the treatment of solid tumors and hematologic malignancies. Yet these, too, have been associated with cardiac toxicity that ranges from a mild asymptomatic decrease in ejection fraction to fulminant myocarditis. In this review, we summarize the cardiotoxic effects of tumor-targeted and immunotherapies with a focus on HER2 antagonists.
PMID: 31988685 [PubMed - in process]
16:00
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:00
In reply to this message
pubmed: ctoall&ca or conall
The Burgeoning Field of Cardio-Oncology.
Related Articles
The Burgeoning Field of Cardio-Oncology.
Methodist Debakey Cardiovasc J. 2019 Oct-Dec;15(4):241-242
Authors: Trachtenberg BH
PMID: 31988683 [PubMed - in process]
16:00
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:00
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:00
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
16:00
In reply to this message
pubmed: ctoall&ca or conall
Barry H. Trachtenberg Leads Issue on Cardio-Oncology.
Related Articles
Barry H. Trachtenberg Leads Issue on Cardio-Oncology.
Methodist Debakey Cardiovasc J. 2019 Oct-Dec;15(4):240
Authors:
PMID: 31988682 [PubMed - in process]
16:00
In reply to this message
pubmed: ctoall&ca or conall
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
Related Articles
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
J Immunother Cancer. 2020 Jan;8(1):
Authors: Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J
No comments:
Post a Comment
اكتب تعليق حول الموضوع